Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [1] that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [2].
|
|
References |
1. Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE. (2024)
The discovery of a potent PARP1 inhibitor Senaparib. Mol Cancer Ther, [Epub ahead of print]. [PMID:38920409] |
2. Cai SX, Tian YE, Dong H, Xu Q, Wu L, Liu L, Jiang Y, Bao , Wang G, Yin F et al.. (2012)
1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof. Patent number: WO2012130166A1. Assignee: Impact Therapeutics, Inc.. Priority date: 01/04/2011. Publication date: 04/10/2012. |
3. Wu X, Liu J, Wang J, Wang L, Lin Z, Wang X, Zhu J, Kong B, Fei J, Tang Y et al.. (2024)
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nat Med, 30 (6): 1612-1621. [PMID:38750351] |